Highest-materiality recent filing
ATEC Q1 rev $192M (+14%), surgical rev +17%; refinances debt with bank facility saving >$6M/yr
Q1 total revenue $192M (14% YoY growth); surgical revenue $178M (+17%) driven by 21% case volume growth.
Director Ward W. Woods retires from Alphatec board; unvested 4,269 RSUs accelerate
Ward W. Woods retires from Board effective Feb 27, 2026 for personal reasons; no disagreement with company.
Alphatec FY2025 revenue $764M (+25% YoY); guides FY2026 ~$890M, raises EBITDA guidance
Full-year 2025 total revenue $764M (+25% YoY); GAAP net loss $143M; non-GAAP net income $8M.
ATEC prelim FY2025 rev ~$764M (+25%), FY2026 outlook $890M; acquires OsteoAdapt distribution rights
Preliminary FY2025 total revenue ~$764M (25% growth); surgical revenue grew 26% with volume up 24%.
ATEC board member Jeffrey P. Rydin passes away at 59 after lengthy illness
Jeffrey P. Rydin, age 59, passed away on November 3, 2025 after a lengthy illness.
ATEC reports Q3 revenue $197M (+30% YoY), raises FY2025 guidance to $760M
Total revenue $197M, surgical revenue $177M (+31% YoY); EOS revenue $20M (+29%).
ATEC Q2 revenue $186M (+27.5% YoY), raises FY revenue and EBITDA guidance
Surgical revenue $168M (+29% YoY); total revenue $186M (+27.5% YoY).
Alphatec stockholders approve doubling authorized shares and equity plan increase
Stockholders approved amendment to increase authorized common stock from 200M to 400M shares.
ATEC Q1 revenue $169M (+22% YoY); raises FY guidance to $734M; refinances convertible debt to 2030
Surgical revenue $152M (+24%), driven by 17% procedural volume growth and 18% new surgeon adoption increase.
Alphatec reduces cash salaries 10-50% for NEOs, grants RSUs vesting in Aug and Dec 2025
Cash base salaries reduced by 10%, 25%, or 50% for NEOs and other executives.
Alphatec issues $405M 0.75% convertibles due 2030, repurchases $253M of 2026 notes
Completed repurchase of $253.0M of its 0.75% convertible senior notes due 2026 on March 10, 2025.
Alphatec issues $405M 0.75% convertible notes due 2030; repurchases $253M 2026 notes
Issued $405M principal of 0.75% Convertible Senior Notes due 2030, including $55M from full exercise of initial purchasers' option.
ATEC prices upsized $350M 0.75% convertible notes due 2030; to repurchase $253M 2026 notes
Pricing of $350M principal (upsized from $300M) of 0.75% convertible senior notes due 2030; initial conversion price ~$15.54 (32.5% premium).
Alphatec announces $300M convertible notes offering due 2030, repurchases part of 2026 notes
Offers $300M aggregate principal of convertible senior notes due 2030; initial purchasers option for additional $50M.
ATEC FY2024 revenue $612M (+27% YoY); guides FY2025 rev ~$732M, positive FCF
FY2024 total revenue $612M, +27% YoY; GAAP net loss $162M; non-GAAP adjusted EBITDA $31M (5% margin).
Alphatec reports prelim 2024 rev ~$611M (+27% YoY); guides 2025 rev $732M, positive FCF
Preliminary full-year 2024 total revenue ~$611M (+27% YoY); surgical revenue up 29% to ~$544M.
ATEC Q3 revenue $151M (+27%), raises FY guidance, adds $50M term loan
Q3 total revenue $151M, up 27% YoY; surgical revenue grew 30%.
ATEC Q2 revenue $146M (+25% YoY); raises FY2024 guidance to $602M rev, ~$25.5M adj EBITDA
Total revenue $146M (+25% YoY); surgical revenue +27%. GAAP net loss $41M; adjusted EBITDA $5.6M (4% margin).
Alphatec annual meeting: four directors depart, Altman gets accelerated vesting of 6,937 RSUs
Four directors (Altman, Meynadier, Mowry, Tullis) not nominated for re-election; terms ended June 12, 2024.
ATEC Q1 revenue up 27% to $138M; raises FY 2024 guidance
Surgical revenue grew 30% YoY on 23% volume increase and 6% higher average revenue per procedure.
Alphatec Holdings discloses holding 2024 Investor Day; no new material information in filing
Filed under Item 7.01 to disclose investor day presentation given March 19, 2024.
Alphatec reports FY2023 revenue $482M (+37% YoY); guides FY2024 revenue ~$595M
Full-year 2023 revenue $482M, up 37% YoY; Q4 revenue $138M, surgical revenue growth 34%.
Effective July 29, 2024, the Company's Board of Directors (“Board”) increased the number of directors to serve on the Board to ten members and appointed Keith Valentine to serve as a director of the Company
Elizabeth Altman, Marie Meynadier, David Mowry and James Tullis were not nominated for re-election at the Annual Meeting and, as such, each of their respective terms as directors concluded following the Annual Meeting.
Elizabeth Altman, Marie Meynadier, David Mowry and James Tullis were not nominated for re-election at the Annual Meeting and, as such, each of their respective terms as directors concluded following the Annual Meeting.
Elizabeth Altman, Marie Meynadier, David Mowry and James Tullis were not nominated for re-election at the Annual Meeting and, as such, each of their respective terms as directors concluded following the Annual Meeting.
Elizabeth Altman, Marie Meynadier, David Mowry and James Tullis were not nominated for re-election at the Annual Meeting and, as such, each of their respective terms as directors concluded following the Annual Meeting.
Max materiality 0.85 · Median 0.75 · Most common event earnings